Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Pacific Daily journalist was involved in the writing and production of this article.
ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
–News Direct–
ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies.
With a contract value of 550,000, the project is scheduled for completion in the first quarter of next year.
Newland said the agreement is an extension of a prior arrangement to develop a methodology for detecting CTC micronuclei and will use ANGLE's innovative Parsortix system. Successful development of this AR assay is expected to bolster the use of the Parsortix system in clinical oncology, particularly for assessing the efficacy of prostate cancer therapies.
The discussion also touched upon the potential benefits of this development for ANGLE, suggesting it might significantly enhance the company's operations and market position.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-484401574
ANGLE PLC
COMTEX_452061216/2655/2024-05-08T08:16:53
« HIVE Digital Technologies CEO Aydin Kilic discusses strategic growth in AI and crypto mining (Previous News)
Related News
Welcome to NeuraSwap—your gateway to decentralized AI finance (AiFi)
Spread the love At the heart of the GPT Protocol, NeuraSwap redefines how we interactRead More
ONIX Exchange Leads the Wave of AI Copy Trading and Financial Innovation
Spread the love ONIX Exchange is at the forefront of integrating artificial intelligence (AI) intoRead More